AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21332375 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 19
Study 19178390 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFC administered in the evening
Number of subjects: 32
Study 19178390 — intervention group
Group type: COMPARATOR
Intervention: TTFC administered in the morning
Number of subjects: 32
Study 17578973 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release epidural morphine (EREM) 10 mg
Number of subjects: 70
Study 17578973 — intervention group
Group type: COMPARATOR
Intervention: Conventional epidural morphine 4 mg
Number of subjects: 70
Study 15190961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 2, 4, and 6 microg x kg(‐1) x min(‐1)
Number of subjects: 16
Study 15190961 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 11464357 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of 0.75% ropivacaine plus 0.5 mL of 0.9% NaCl (solution A)
Number of subjects: 60
Study 11464357 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.75% ropivacaine plus 0.0012 mEq of NaHCO(3) (solution B)
Number of subjects: 60
Study 11464357 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.75% ropivacaine (with adrenaline) plus 0.015 mEq of NaHCO(3) (solution C)
Number of subjects: 60
Study 9542366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape recorded Western music
Number of subjects: 38
Study 9542366 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 38
Study 7804502 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education programs
Number of subjects: 497
Study 7804502 — intervention group
Group type: COMPARATOR
Intervention: Perceived serostatus or recent testing
Number of subjects: 497
Study 3201506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal shunting
Number of subjects: 118
Study 3201506 — intervention group
Group type: COMPARATOR
Intervention: No shunting (Control)
Number of subjects: 118
Study 31305114 — intervention group
Group type: EXPERIMENTAL
Intervention: AWARE intervention (n = 32)
Number of subjects: 63
Study 31305114 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 31)
Number of subjects: 63
Study 27724149 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Review Committee (IRC) assessment
Number of subjects: 447
Study 27724149 — intervention group
Group type: COMPARATOR
Intervention: Unblinded investigators assessment
Number of subjects: 447
Study 25808588 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α inhibitors (adalimumab, infliximab, etanercept, certolizumab pegol, golimumab)
Number of subjects: 495
Study 23422159 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Number of subjects: 0
Study 21990966 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing plus confirmatory HTC (parallel testing with two rapid finger-prick blood tests)
Number of subjects: 298
Study 21990966 — intervention group
Group type: COMPARATOR
Intervention: Standard HTC alone
Number of subjects: 298
Study 21990966 — intervention group
Group type: COMPARATOR
Intervention: No testing
Number of subjects: 298
Study 18328151 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program (five-weekly sessions)
Number of subjects: 60
Study 18328151 — intervention group
Group type: COMPARATOR
Intervention: Weekly medical visits (control group)
Number of subjects: 60
Study 16691029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL, 80 mg, morning administration
Number of subjects: 236
Study 16691029 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin XL, 80 mg, evening administration
Number of subjects: 236
Study 14552534 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal attention characteristics group
Number of subjects: 2
Study 14552534 — intervention group
Group type: COMPARATOR
Intervention: Attention deficit group
Number of subjects: 2
Study 11083178 — intervention group
Group type: EXPERIMENTAL
Intervention: SENIC index
Number of subjects: 196
Study 11083178 — intervention group
Group type: EXPERIMENTAL
Intervention: NNIS index
Number of subjects: 196
Study 11083178 — intervention group
Group type: EXPERIMENTAL
Intervention: Residuals of SENIC index
Number of subjects: 196
Study 11083178 — intervention group
Group type: EXPERIMENTAL
Intervention: Residuals of NNIS index
Number of subjects: 196
Study 8665116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (1 mg norethindrone and 35 micrograms ethinyl oestradiol) for 21 days, n = 7
Number of subjects: 10
Study 8665116 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 3
Number of subjects: 10
Study 8665116 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 10
Study 8665116 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 10
Study 8665116 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance test during follicular phase
Number of subjects: 10
Study 8665116 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance test during luteal phase
Number of subjects: 10
Study 1387301 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg oral tablet formulation 1
Number of subjects: 22
Study 1387301 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg oral tablet formulation 2
Number of subjects: 22
Study 1387301 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of the lactobionate salt
Number of subjects: 22
Study 1387301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dosing of clarithromycin
Number of subjects: 22
Study 1387301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis of clarithromycin
Number of subjects: 22
Study 6486186 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal praise
Number of subjects: 66
Study 6486186 — intervention group
Group type: EXPERIMENTAL
Intervention: Edible reward
Number of subjects: 66
Study 6486186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 66
Study 6486186 — intervention group
Group type: COMPARATOR
Intervention: Nonreinforcement phases
Number of subjects: 66
Study 6486186 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MA groups
Number of subjects: 66
Study 31053943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab therapy
Number of subjects: 20
Study 31053943 — intervention group
Group type: COMPARATOR
Intervention: Contralateral non-exudative AMD eyes (Control)
Number of subjects: 20
Study 29284534 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural catheter (PNC) with continuous local anaesthetic infusion for the first 5 postoperative days
Number of subjects: 50
Study 29284534 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative analgesia
Number of subjects: 50
Study 29284534 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 2 and 6 months post-surgery
Number of subjects: 50
Study 27044596 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 180
Study 27044596 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 180
Study 27044596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch)
Number of subjects: 180
Study 24330343 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oxymorphone ER after a high-fat meal
Number of subjects: 30
Study 24330343 — intervention group
Group type: COMPARATOR
Intervention: 40 mg oxymorphone ER after fasting
Number of subjects: 30
Study 22269272 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable fixation systems (Inion CPS)
Number of subjects: 230
Study 22269272 — intervention group
Group type: COMPARATOR
Intervention: Titanium fixation systems (KLS Martin)
Number of subjects: 230
Study 21117499 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product Lipivim (200 mg fenofibrate)
Number of subjects: 24
Study 21117499 — intervention group
Group type: COMPARATOR
Intervention: Reference product (200 mg fenofibrate)
Number of subjects: 24
Study 17212680 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine (DHEP) 65-mg sachet
Number of subjects: 155
Study 17212680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 17212680 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine (DHEP)
Number of subjects: 155
Study 15144464 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofleponide palmitate 400 microg
Number of subjects: 40
Study 15144464 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 128 microg
Number of subjects: 40
Study 15144464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12351301 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind intubation with a gum-elastic bougie (Group 1)
Number of subjects: 60
Study 12351301 — intervention group
Group type: COMPARATOR
Intervention: Indirect laryngoscopy with a laryngeal mirror (Group 2)
Number of subjects: 60
Study 12351301 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 9700984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg/day)
Number of subjects: 0
Study 9700984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8027290 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU/day kallikrein
Number of subjects: 44
Study 8027290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 8027290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (kallikrein and placebo)
Number of subjects: 44
Study 2604760 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking on a treadmill for 60 min
Number of subjects: 23
Study 2604760 — intervention group
Group type: COMPARATOR
Intervention: Sitting in a chair for 60 min
Number of subjects: 23
Study 781495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg per day)
Number of subjects: 16
Study 781495 — intervention group
Group type: EXPERIMENTAL
Intervention: Prindolol (10 mg three times per day)
Number of subjects: 16
Study 781495 — intervention group
Group type: EXPERIMENTAL
Intervention: Prindolol (10 mg three times per day) + Hydrochlorothiazide (50 mg per day)
Number of subjects: 16
Study 781495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 16
Study 31331578 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage with olive oil
Number of subjects: 0
Study 31331578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28575274 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 15828
Study 28575274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15828
Study 26282657 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral intervention supplemented with telephone counseling and tailored newsletters
Number of subjects: 692
Study 26282657 — intervention group
Group type: COMPARATOR
Intervention: Less intensive control intervention
Number of subjects: 692
Study 26282657 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral intervention
Number of subjects: 692
Study 21845501 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (gpc training for oral reading and spelling, orthographic spelling strategy, RAP training, morphological strategies)
Number of subjects: 24
Study 21845501 — intervention group
Group type: COMPARATOR
Intervention: Treatment B (gpc training for oral reading and phonological awareness, continued step 2 training, orthographic spelling strategy training)
Number of subjects: 24
Study 21845501 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (RAP training during step 3)
Number of subjects: 24
Study 22123798 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered intervention (quarterly educational modules, practice guidelines, monthly literature summaries, automated e-mail reminders) for 27 months
Number of subjects: 15847
Study 22123798 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (standard care)
Number of subjects: 15847
Study 22123798 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered intervention
Number of subjects: 15847
Study 22123798 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 15847
Study 19090555 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30
Study 19090555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17035947 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (a single dose of 18.4 Gy)
Number of subjects: 25
Study 17035947 — intervention group
Group type: COMPARATOR
Intervention: Sham radiation (Control)
Number of subjects: 25
Study 12964797 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE Surgical resorbable blast media (RBM) dental implant
Number of subjects: 348
Study 10846695 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 days of treatment with clarithromycin 500 mg, amoxicillin 1 g and omeprazole 20 mg, b.i.d.
Number of subjects: 223
Study 10846695 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of treatment with clarithromycin 500 mg, amoxicillin 1 g and omeprazole 20 mg, b.i.d.
Number of subjects: 223
Study 9356566 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Disorder Severity Scale
Number of subjects: 186
Study 9356566 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Disorder Severity Scale (after short-term treatment)
Number of subjects: 186
Study 9356566 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Disorder Severity Scale (individual items)
Number of subjects: 186
Study 8259896 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMG-BF)
Number of subjects: 192
Study 8259896 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 192
Study 3769163 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone alone (group 1, 20 patients)
Number of subjects: 37
Study 3769163 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus type IA agent (group 2, 17 patients)
Number of subjects: 37
Study 3769163 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (administered during amiodarone therapy)
Number of subjects: 37
Study 30746574 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoLap™ system
Number of subjects: 30
Study 30746574 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 30589027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated SIB-IMRT at 3.6 Gy/f (total of 72 Gy/20 fractions) combined with temozolomide (TMZ) at 75 mg/m2/day during radiotherapy and 150-200 mg/m2/day for 5 days every 28 days.
Number of subjects: 16
Study 30589027 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated SIB-IMRT at 4 Gy/f (considered dose-limiting toxicity)
Number of subjects: 16
Study 30589027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated SIB-IMRT at 3.6 Gy/f (MTD)
Number of subjects: 16
Study 26439785 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE (5 g of CRE monohydrate, 4 times per day; n = 14)
Number of subjects: 54
Study 26439785 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE + CAF (CRE + 300 mg·d of CAF; n = 13)
Number of subjects: 54
Study 26439785 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE + COF (CRE + 8.9 g of COF, yielding 303 mg of CAF; n = 13)
Number of subjects: 54
Study 26439785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; n = 14)
Number of subjects: 54
Study 26439785 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 54
Study 26439785 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE + CAF
Number of subjects: 54
Study 25317071 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise with amino acid supplementation (RT)
Number of subjects: 31
Study 25317071 — intervention group
Group type: COMPARATOR
Intervention: Amino acid supplementation alone (EAA)
Number of subjects: 31
Study 23229691 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravitreal triamcinolone acetonide
Number of subjects: 0
Study 23229691 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone acetonide
Number of subjects: 0
Study 23229691 — intervention group
Group type: COMPARATOR
Intervention: Standard care (observation for SCORE-CRVO trial and grid photocoagulation for SCORE-BRVO trial)
Number of subjects: 0
Study 23229691 — intervention group
Group type: COMPARATOR
Intervention: Standard care and triamcinolone treatments
Number of subjects: 0
Study 19464461 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-I group (1 minimum alveolar concentration of sevoflurane for 5 minutes)
Number of subjects: 30
Study 19464461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-II group (2 cycles of 5 minutes of sevoflurane with 5-minute washout)
Number of subjects: 30
Study 19464461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 30
Study 17975455 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation interventions
Number of subjects: 491
Study 17975455 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent assessment
Number of subjects: 491
Study 17975455 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF Participation assessment
Number of subjects: 491
Study 17975455 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of outcomes
Number of subjects: 491
Study 15602501 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral D‐amphetamine
Number of subjects: 96
Study 15602501 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral D‐amphetamine
Number of subjects: 96
Study 15602501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 11948270 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids (highest quartiles)
Number of subjects: 278
Study 11948270 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of long-chain n-3 fatty acids
Number of subjects: 278
Study 9802935 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPH-350
Number of subjects: 20
Study 9802935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig-Therasorb
Number of subjects: 20
Study 7663009 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 31
Study 7663009 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin + alpha-interferon
Number of subjects: 31
Study 7663009 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 31
Study 7663009 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 31
Study 2570958 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 101
Study 2570958 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 101
Study 58651 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antihuman thymocyte globulin (HAHTG) combined with prednisone and azathioprine (lmuran)
Number of subjects: 50
Study 58651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HAHTG)
Number of subjects: 50
Study 58651 — intervention group
Group type: EXPERIMENTAL
Intervention: HAHTG group
Number of subjects: 50
Study 30463070 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multicomponent exercise program
Number of subjects: 112
Study 30463070 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study 30463070 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline myostatin levels
Number of subjects: 112
Study 27749731 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (TD)
Number of subjects: 25
Study 27749731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramidal Resistance Training (PR)
Number of subjects: 25
Study 27749731 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 25
Study 26138180 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Zotarolimus Eluting Stent (R-ZES)
Number of subjects: 100
Study 23318559 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (twice normal dietary levels)
Number of subjects: 100
Study 23318559 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study 21113584 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training group (ET)
Number of subjects: 60
Study 21113584 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 60
Study 18681892 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple eradication therapy + Saccharomyces boulardii (250 mg b.i.d. for 4 weeks)
Number of subjects: 90
Study 18681892 — intervention group
Group type: COMPARATOR
Intervention: Standard triple eradication therapy (omeprazole/esomeprazole, amoxicillin and clarithromycin)
Number of subjects: 90
Study 18681892 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple eradication therapy + Saccharomyces boulardii
Number of subjects: 90
Study 18681892 — intervention group
Group type: COMPARATOR
Intervention: Standard triple eradication therapy
Number of subjects: 90
Study 16626572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow mononuclear cells transplantation
Number of subjects: 35
Study 16626572 — intervention group
Group type: COMPARATOR
Intervention: Standard drug therapy and percutaneous coronary intervention (PCI)
Number of subjects: 35
Study 14716843 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhaoyangwan (ZYW)
Number of subjects: 50
Study 14716843 — intervention group
Group type: COMPARATOR
Intervention: Interferon (Control)
Number of subjects: 50
Study 11696746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory urodynamics
Number of subjects: 106
Study 11696746 — intervention group
Group type: COMPARATOR
Intervention: Video cystometry
Number of subjects: 106
Study 9477031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive approach treatment (n = 9)
Number of subjects: 21
Study 9477031 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation component treatment (n = 12)
Number of subjects: 21
Study 9477031 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 8203876 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow stroke effleurage back rub
Number of subjects: 32